Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan;5(1):62-71.
doi: 10.1038/s41570-020-00229-2. Epub 2020 Oct 21.

Exploring new targets and chemical space with affinity selection-mass spectrometry

Affiliations
Review

Exploring new targets and chemical space with affinity selection-mass spectrometry

Renaud Prudent et al. Nat Rev Chem. 2021 Jan.

Abstract

Affinity selection-mass spectrometry (AS-MS) is a high-throughput screening (HTS) technique for drug discovery that enables rapid screening of large collections of compounds to identify ligands for a specific biomolecular target. AS-MS is a binding assay that is insensitive to the functional effects a ligand might have, which is important because it lets us identify novel ligands irrespective of their binding site. This approach is gaining popularity, notably due to its role in the emergence of useful agents for targeted protein degradation. This Perspective highlights the use of AS-MS techniques to explore broad chemical space and identify small-molecule ligands for biological targets that have proven challenging to address with other screening paradigms. We present chemical structures of reported AS-MS hits to illustrate the potential of this screening approach to deliver high-quality hits for further optimization. AS-MS has, thus, evolved from being an infrequent alternative to traditional HTS or DNA-encoded library strategies to now firmly establishing itself as a HTS approach for drug discovery.

PubMed Disclaimer

References

    1. Mignani, S., Huber, S., Tomás, H., Rodrigues, J. & Majoral, J.-P. Why and how have drug discovery strategies in pharma changed? What are the new mindsets? Drug Discov. Today 21, 239–249 (2016). - PubMed
    1. Erlanson, D. A., McDowell, R. S. & O’Brien, T. Fragment-based drug discovery. J. Med. Chem. 47, 3463–3482 (2004). - PubMed
    1. Erlanson, D. A., Fesik, S. W., Hubbard, R. E., Jahnke, W. & Jhoti, H. Twenty years on: the impact of fragments on drug discovery. Nat. Rev. Drug Discov. 15, 605–619 (2016). - PubMed
    1. Yuen, L. H. & Franzini, R. M. Achievements, challenges, and opportunities in DNA-encoded library research: an academic point of view. ChemBioChem 18, 829–836 (2017). - PubMed
    1. Annis, D. A. et al. An affinity selection–mass spectrometry method for the identification of small molecule ligands from self-encoded combinatorial libraries: Discovery of a novel antagonist of E. coli dihydrofolate reductase. Int. J. Mass. Spectrom. 238, 77–83 (2004).

LinkOut - more resources